FIA
FTH

FNY Investment Advisers’s Faeth Therapeutics FTH Stock Holding History

FNY Investment Advisers’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-175
Closed -$8K – 883
2022
Q1 		$8K Buy
+175
New +$13.9K 0.01% 489

Other funds holding FTH

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FNY Investment Advisers's FTH Position: Q2 2022 in Review

FNY Investment Advisers sold out of Faeth Therapeutics (FTH) in Q2 2022, closing a stake of 175 shares — an estimated $8K sold.

FNY Investment Advisers first reported a position in FTH in Q1 2022 and held it in 1 quarter. The position peaked at $8K in Q1 2022. 39 funds tracked by Wall St. Rank hold FTH as of Q2 2022.

  • FNY Investment Advisers reported no remaining Faeth Therapeutics position as of Q2 2022 after selling out during the quarter.
  • FNY Investment Advisers sold 175 Faeth Therapeutics shares in Q2 2022, an estimated $8K.
  • FNY Investment Advisers first reported a position in Faeth Therapeutics in Q1 2022 and held it in 1 quarter.
  • FNY Investment Advisers's Faeth Therapeutics position peaked at $8K in Q1 2022.
  • 39 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2022.

Based on FNY Investment Advisers's 13F filing for Q2 2022, filed 12 Jul 2022.